Gregory Wickern, MD
Allergy · Twin Falls, IDNPI 1972578672
Payments from drug & device makers
Across 381 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Grifols USA, LLC$987
- Regeneron Healthcare Solutions, Inc.$941
- CSL Behring$725
- Takeda Pharmaceuticals U.S.A., Inc.$704
- GSK$503
- plus $3K from 28 others
What the payments were for
- Consulting fees$481%
- Food & beverage$7,75898%
- Education$791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 79 | $1,514 |
| Grifols USA, LLC | 53 | $987 |
| Regeneron Healthcare Solutions, Inc. | 42 | $941 |
| CSL Behring | 29 | $725 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $704 |
| GSK | 49 | $503 |
| Blueprint Medicines Corporation | 12 | $463 |
| Octapharma USA, Inc. | 4 | $246 |
| Sanofi | 11 | $215 |
| Teva Pharmaceuticals USA, Inc. | 9 | $207 |
| Mylan Specialty L.p. | 7 | $174 |
| Pfizer | 8 | $127 |
| Amgen(2 entities) | 5 | $119 |
| Aimmune Therapeutics, Inc. | 5 | $113 |
| Biocryst US Sales Co., LLC | 3 | $94 |
| Pharming Healthcare, Inc. | 4 | $78 |
| Merck | 1 | $75 |
| ADMA Biomanufacturing LLC | 3 | $71 |
| Sanofi US Services Inc. | 1 | $67 |
| Boehringer Ingelheim | 4 | $58 |
| Genentech USA, Inc. | 3 | $57 |
| Ionis Pharmaceuticals, Inc. | 2 | $51 |
| Organon | 2 | $40 |
| Optinose US, Inc. | 2 | $33 |
| Shire North American Group Inc | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Verona Pharma, Inc. | 1 | $27 |
| X4 Pharmaceuticals, Inc. | 1 | $27 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| LEO Pharma Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 32 | $325,781 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 23 | $249,197 |
| Dupixent SyringeDupilumab | 13 | $48,648 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $40,623 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $8,922 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,693 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $7,415 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $3,754 |
| Ipratropium Bromide | 87 | $3,065 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,826 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $1,957 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,907 |
| Azelastine Hcl | 65 | $853 |
| Roflumilast | 12 | $462 |
| Hydroxychloroquine Sulfate | 15 | $450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $725 | $325,78132 claims |
| Grifols USA, LLCProlastin C | $987 | $249,19723 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $503 | $49,54561 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,514 | $12,44731 claims |
| Boehringer IngelheimStiolto Respimat | $58 | $7,41516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other allergy in Twin Falls
- Richard HenryTwin Falls$27K
- David PettyIdaho Falls$12K
- Charles WebbBoise$6K
- David ParryPocatello$59
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.